Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BACH study of patient choice versus randomization for filgotinib or TNF inhibitor in active rheumatoid arthritis
NL-OMON52329Phase 4Recruiting
- Sponsor
- Medisch Centrum Leeuwarden
- Start
- May 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of filgotinib, adalimumab and etanercept in rheumatoid arthritis (RA), sponsored by Medisch Centrum Leeuwarden. Primary endpoints: Proportion choosing filgotinib at baseline and Treatment satisfaction. Started May 2021; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON52329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52329.